C Crandall, JP Pregler, E Warner, DB … - Annals of Internal …, 2005 - Am Coll Physicians Women with mutations of the BRCA1 and BRCA2 genes have a lifetime breast cancer risk of
50% to 85%. Routine mammography detects approximately 50% of tumors in women with the
mutation versus 75% of tumors in women who do not have the mutation (1). Decreased ... Related articles - All 4 versions
K Pharmakologie, B Mitte gGmbH, A Lehrkrankenhaus - aok-gesundheitspartner.de 1. Für eine Änderung der Empfehlung, die primäre 5-jährige Anwendung von Tamoxifen in der
adju- vanten Behandlung des hormonrezeptorpositiven Mammakarzinoms postmenopausaler
Frauen zu bevorzugen, gibt es nach wie vor keine valide Begründung. Eine Reduktion ... Related articles - View as HTML - All 3 versions
S Black - ctgoingthedistance.com The Ovarian Cancer National Alliance salutes the development of the first national consensus
statement on ovarian cancer symptoms. The Alliance has advocated for a consensus statement
on symptoms ever since the organization's founding in 1997. The Alliance was created to ... Related articles - View as HTML
J Doimer - ovarianawarenessofky.org In the late 1990s, Dr. Barbara Goff, a gynecologic oncologist at the University of Washington,
worked hand-in-hand with one of our co-founders, the late Cindy Melancon, to develop and disseminate
a symptoms survey in Cindy's ovarian cancer survivors' newsletter. The results dispelled ... Related articles - View as HTML
W Advocate, A Info, U Links, S Stories, I Memory - sloca.org In the late 1990s, Dr. Barbara Goff, a gynecologic oncologist at the University of Washington
, worked hand-in-hand with one of our co-founders, the late Cindy Melancon, to develop and
disseminate a symptoms survey in Cindy's ovarian cancer survivors' newsletter. The ... Related articles - Cached
EP Winer - Advanced Studies in Medicine - jhasim.com The Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial was the first large,
randomized, double-blind study to show that treatment with an aromatase inhibitor (AI) improves
clinical outcomes in postmenopausal women receiving adjuvant endocrine therapy for ... Related articles - All 4 versions
SE Jones - Clinical breast cancer, 2006 - CIG Media Group Introduction The aromatase inhibitors (AIs) have proven to be more ac- tive than tamoxifen in
the metastatic setting and according- ly have rapidly moved into the adjuvant setting. Several
well-designed clinical trials have provided the basis for the initial Food and Drug ... Cited by 21 - Related articles - All 3 versions
K Gibson, CL O'Bryant - Journal of Oncology Pharmacy Practice, 2008 - opp.sagepub.com Objective. Breast cancer patients are at an increased risk of osteoporosis due to age,
cancer, chemother- apy, and aromatase inhibitor therapy. This retrospec- tive review determined
if patients treated with aromatase inhibitors received appropriate screening and ... Related articles - All 2 versions
VOG PRAKSIS - UGESKR LÆGER, 2007 - ugeskriftet.dk Den adjuverende behandling af patienter med primær ope- rabel brystkræft blev introduceret
i Danmark i 1977 inden for rammerne af Danish Breast Cancer Cooperative Group (DBCG).
Postmenopausale patienter med positiv østrogen- og/eller progesteronreceptorstatus ... Related articles - View as HTML - All 2 versions
- ►ascopubs.org CA Hudis, WE Barlow, JP Costantino, RJ Gray … - Journal of Clinical …, 2007 - jco.ascopubs.org Purpose Standardized definitions of breast cancer clinical trial end points must be adopted to
permit the consistent interpretation and analysis of breast cancer clinical trials and to facilitate
cross-trial comparisons and meta-analyses. Standardizing terms will allow for uniformity ... Cited by 38 - Related articles - All 6 versions
